iNCOVACC Intra-Nasal Covid Vaccine: Bharat Biotech International Limited announced on Monday (28 November) that Incovacc (iNCOVACC BBV154) has become the world’s first covid vaccine to be administered through the nose (without a needle). In English it is called Intra-Nasal Covid Vaccine.
The company said in a press release that the Central Drugs Standard Control Organization (CDSCO) has approved both its dosage forms – primary series and heterologous – for all adults under controlled use in emergency situations. This means that people of 18 years of age or older in India can be given its dosage under controlled use in case of emergency.
Bharat Biotech said this in the statement
According to Bharat Biotech’s statement, iNCOVACC can be kept at two to eight degrees Celsius for easy storage and distribution. Bharat Biotech says that this vaccine given through the nose has been specially designed and developed according to low and middle income countries. The vaccine has been developed in partnership with Washington University in St Louis, Missouri, USA.
News Reels
According to the company, the vaccine went through a three-phase clinical trial. Vaccine recipients have been tested and after successful results, it has been specially developed to be administered through a nasal drop. According to the statement, the product development and clinical trials were partially funded by the Government of India.
iNCOVACC, World’s first intranasal vaccine to receive both primary series and heterologous booster approval. #bharatbiotech #incovacc #intranasalvaccine #vaccine #COVID19 #VaccinesWork #VaccineDevelopment #booster #covid #pandemic #firstintranasalvaccine pic.twitter.com/jyTebvwiT6
— BharatBiotech (@BharatBiotech) November 28, 2022
Chairman and Managing Director of Bharat Biotech said this
Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech said, “iNCOVACC is an intranasal vaccine for a primary 2-dose schedule and heterologous booster dose. This is a major achievement for us and the global scientific community to enable nasal administration of the Covid vaccine.” So that we are well prepared with platform technology for future infectious diseases.
Read this also- Collegium System: Center returns 20 files related to appointment of High Court judges to Supreme Court Collegium
